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Abstract
Probiotic yogurt and milk supplemented with probiotics have been investigated for their role in ‘low-grade’ inﬂammation but evidence for
their efﬁcacy is inconclusive. This study explores the impact of probiotic yogurt on metabolic and inﬂammatory biomarkers, with a parallel
study of gut microbiota dynamics. The randomised cross-over study was conducted in fourteen healthy, young men to test probiotic yogurt
compared with milk acidiﬁed with 2% D-(+)-glucono-δ-lactone during a 2-week intervention (400 g/d). Fasting assessments, a high-fat meal
test (HFM) and microbiota analyses were used to assess the intervention effects. Baseline assessments for the HFM were carried out after a run-
in during which normal milk was provided. No signiﬁcant differences in the inﬂammatory response to the HFM were observed after probiotic
yogurt compared with acidiﬁed milk intake; however, both products were associated with signiﬁcant reductions in the inﬂammatory response
to the HFM compared with the baseline tests (assessed by IL6, TNFα and chemokine ligand 5) (P< 0·001). These observations were
accompanied by signiﬁcant changes in microbiota taxa, including decreased abundance of Bilophila wadsworthia after acidiﬁed milk
(log 2-fold-change (FC)= –1·5, Padj= 0·05) and probiotic yogurt intake (FC= –1·3, Padj= 0·03), increased abundance of Biﬁdobacterium
species after acidiﬁed milk intake (FC= 1·4, Padj= 0·04) and detection of Lactobacillus delbrueckii spp. bulgaricus (FC= 7·0, Padj< 0·01) and
Streptococcus salivarius spp. thermophilus (FC= 6·0, Padj< 0·01) after probiotic yogurt intake. Probiotic yogurt and acidiﬁed milk similarly
reduce postprandial inﬂammation that is associated with a HFM while inducing distinct changes in the gut microbiota of healthy men. These
observations could be relevant for dietary treatments that target ‘low-grade’ inﬂammation.
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The inﬂuence of the gut microbiota on health and disease has
become increasingly evident over the last decade(1). The evo-
lution in high-throughput sequencing has been critical in
enabling the study of the microbiota. Indeed, several large
collaborative studies have characterised distinct microbiota
patterns relating to disease risk(2,3). In the context of the
increasing prevalence of obesity and type 2 diabetes mellitus, it
is striking that gut microbiota composition appears to be dif-
ferent in animals and humans with such diseases, compared
with healthy controls(3–5). Thus, the gut microbiota has been
identiﬁed as an important, potentially modiﬁable factor that
contributes to conditions of metabolic dysfunction.
Dietary modulation of the gut microbiota composition
using fermented products containing speciﬁc probiotics has
been practiced for many years as part of nutritional therapy(6).
Deﬁned as ‘live micro-organisms that provide beneﬁts
to the host when administered in adequate quantities’(7), pro-
biotics have been extensively studied in relation to health
promotion and disease prevention, both as additives to dairy
products and as isolated bacterial strains(8). The efﬁcacy of
probiotics in promoting health remains disputed, and results
differ depending on the outcome of interest, choice of the
probiotic strain, formulation of the probiotic and duration of the
intervention.
Abbreviations: CCL5, chemokine ligand 5; CFU, colony-forming units; FC, log 2-fold-change; HFM, high-fat meal test; LGG, Lactobacillus rhamnosus GG;
LPS, lipopolysaccharide; OTU, operational taxonomic unit.
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The use of probiotics to improve metabolic health is a
relatively new indication for probiotic treatment. Of particular
interest is the potential for probiotics to modulate inﬂammatory
status, as demonstrated both in cell culture(9) and in some human
studies(9–11). Chronic, ‘low-grade’ inﬂammation is widely recog-
nised as playing a role in the pathological process leading to
metabolic disease(12). Furthermore, inﬂammation in the case of
metabolic disorders has been associated with changes of the
intestinal microbiota that appear to be in part modulated by the
gut-derived factor, lipopolysaccharide (LPS). Indeed, Cani et al.
demonstrated that LPS can induce an inﬂammation that mimics
inﬂammation that is induced by a high-fat meal(13), and proposed
that a high-fat diet could contribute to inﬂammation by increasing
the transfer of LPS derived from the gut microbiota across the
intestinal barrier(14). The modulation of inﬂammatory status by
dietary intervention, particularly during the early stages of
metabolic dysfunction, could thus form a useful part of disease
prevention.
Despite the potential for probiotics to modulate metabolic
health by gut microbiota-related mechanisms, the gut micro-
biota is not always assessed in intervention studies that consider
the effect of probiotics on metabolic health outcomes(11,15,16),
and in cases where analysis is completed, targeted or semi-
targeted approaches are often adopted(9,10). The development
of untargeted metagenomic techniques, such as 16S sequen-
cing, offers a more comprehensive approach to understand
how the gut microbiota might be inﬂuenced by these dietary
interventions.
Milk can modulate both the inﬂammatory response(17) and
the composition of the gut microbiota(18). As dairy products are
important vectors for the delivery of probiotics to humans, in
the present study, we explore the impact of two dairy product
dietary interventions on metabolic and inﬂammatory outcomes,
with parallel evaluation of the faecal microbiota dynamics. First,
we test the hypothesis that a probiotic yogurt, compared with
milk acidiﬁed with glucono-δ-lactone, can reduce transient
inﬂammation induced by a high-fat meal challenge. The
validated test models a metabolic stimulus which aims to mimic
the inﬂammatory stress that precedes metabolic dysfunction(19).
Second, we test the hypothesis that these interventions alter the
gut microbial composition.
Methods
Subjects
A total of fourteen healthy young men were recruited by a
poster campaign (December 2013–March 2014). Inclusion
criteria were applied to select subjects aged 18–40 years with a
stable, healthy BMI (18·5–25·0 kg/m2), regular dietary and
physical activity habits, and no evidence of dietary intolerances,
restrictions or adverse reactions to dairy products. Exclusion
criteria included chronic or acute disease, hypertension, regular
medication, moderate or intense physical activity (exceeding
6 h/week), nutritional supplements, antibiotic treatment in the
6 months preceding the study and a history of anaemia. These
criteria were veriﬁed during an inclusion visit that included a
physical medical examination, dietary and physical activity
assessments, standard anthropometrics and bioimpedance
analysis (ImpDF50; ImpediMed). Fasting glycaemia, insulinaemia,
lipid proﬁle, full blood count and Fe proﬁle were evaluated.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the regional committee
for human experimentation (approval no.: 392/13, Vaud,
Switzerland). Written informed consent was obtained from all
subjects. The trial was registered at clinicaltrial.gov (registration
number: NCT02230345).
Interventions
Two dairy products were tested during the study: yogurt con-
taining the probiotic Lactobacillus rhamnosus GG (LGG) (ATCC
53103) and milk acidiﬁed with D-(+)-glucono-δ-lactone (2%) in
order to mimic texture, pH and physical properties of the yogurt.
All dairy products provided during the study were derived from
the same batch of full-fat homogenised, ultra-high-temperature-
treated milk (3·5%) that was supplied by Emmi AG. The probiotic
yogurt was prepared by fermentation using Lactobacillus
delbrueckii spp. bulgaricus and Streptococcus thermophilus
(Thermophilic Yoﬂex® culture; Chr. Hansen) (online Supple-
mentary Methods). Bacterial counts were carried out for the
production batches to conﬁrm a minimum of 1·00×106 colony-
forming units (CFU)/g per strain: L. delbrueckii spp. bulgaricus
9·04×107 (SD 3·55×107)CFU/g, S. thermophilus 6·50×108
(SD 1·04×108)CFU/g and LGG 2·83×106 (SD 6·53×105) CFU/g
(online Supplementary Fig. S1). Participants consumed dairy
products that were between 4 and 15d post-production. The
nutritional composition of the products is detailed in the online
Supplementary Table S1.
Experimental design
The experimental design followed the structure of a rando-
mised, double-blind, cross-over trial (Fig. 1(a)). This procedure
was used to evaluate the postprandial and short-term effects of
the two dairy products investigated, probiotic yogurt and
acidiﬁed milk. The dairy products were randomly allocated to
volunteers (seven volunteers per test sequence). Each product
was tested over a 2-week intervention phase.
Two distinct types of postprandial tests were carried out
during the study: (1) dairy product test (D1, D2) and (2) high-fat
meal test (HFM) (HFM1, HFM2 and HFM3). The ﬁrst type of test
evaluated the postprandial response to a single dose of the
assigned dairy product (800 g of probiotic yogurt or acidiﬁed
milk). This was conducted on the ﬁrst day of each test phase.
The test marked the beginning of the daily intake phase that
required a daily consumption of 400 g (as per Swiss guidelines
for recommended dairy product intake(20)) of the assigned dairy
product for 2 weeks. At the end of this period, a second type of
postprandial test was carried out to assess whether the daily
intake of probiotic yogurt or acidiﬁed milk could inﬂuence the
response to a meal that normally induces a state of transient
inﬂammation. This test used a mixed-meal challenge (adapted
from Schwander et al.(19)) formulated to contain an elevated
quantity of energy in the form of saturated fat and sugar, and no
dairy products (Table 1). The baseline measurements for this
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test were completed during a run-in period that preceded the
ﬁrst intervention (HFM1 in Fig. 1(a)). During this 4-week run-in
period, a ﬁxed dose (400ml/d) of full-fat milk was provided to
the volunteers to normalise the background dairy product
intake before the two dairy product interventions. The same
conditions were applied during two 3-week wash-out phases
that followed each intervention period.
Dietary and lifestyle restrictions
Dietary restrictions and assessments were completed during all
study phases with additional monitoring of physical activity.
Participants were asked to maintain a stable level of physical
activity, comparable with their usual pattern of activity, during
the study and to avoid intense physical activity during the 3 d
preceding each test day. This was evaluated by ActiGraph
wGT3X accelerometers (ActiGraph) worn on the waist during
ﬁve phases of the study: run-in, test phases (1, 2) wash-out
phases (1, 2). Accelerometers recorded data in 60 s epochs.
Dietary intake was semi-controlled during the study. Dietary
restrictions excluded all dairy products not provided by the study
organisers and included speciﬁc guidance on portions of fer-
mented foods, alcohol intake and caffeine intake to replicate
normal baseline eating patterns. During each test phase of the
study, 3-d self-completed dietary records (including 1 weekend
day) were completed. In addition, participants self-reported
compliance with the assigned dairy product using a daily
record. Before each of the ﬁve test days, participants followed a
3-d controlled diet (55% carbohydrate, 30% fat, 15% protein – an
example menu is available in the online Supplementary Table S2)
(Fig. 1(a), control diet 1–5 (CD1–CD5)). All foods were provided
by the study organisers but consumed under free-living condi-
tions. Portions were adapted to meet individual nutritional
requirements (estimations completed using the Harris–Benedict
equations and physical activity levels 1·5–1·7). Product tolerance
and well-being was assessed during each test phase intervention.
Study days
All ﬁve test days were completed at the Centre of Clinical
Research, Lausanne, Switzerland. On each test day, the participants
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Fig. 1. Overview of the study design. (a) Participants were assigned randomly to group 1 or group 2 to test the probiotic yogurt and acidified milk in a cross-over
design. Wash-out periods followed each test phase and a run-in preceded the beginning of the study. (b) Metabolic and inflammatory assessments. , Evaluations on
dairy product test; , evaluations on high-fat meal test; CD1–5, control diet 1–5; HFM1–3, high-fat meal test days 1–3; D1–2, dairy product test day 1–2; FS1–8, faecal
samples 1–8; HOMA, homoeostatic model assessment; hsCRP, high-sensitivity C-reactive protein; CCL2, chemokine ligand 2; CCL5, chemokine ligand 5.
Table 1. Composition of the high-fat meal test (HFM) used to induce
postprandial inflammation*
Nutritional content of HFM (per portion)
Bread Palm fat Salami Eggs Total % Energy
Weight (g) 116·0 20·0 104·0 52·0 292·0
Energy (MJ) 1·3 0·8 1·5 0·3 3·9
Carbohydrate (g) 55·7 0·0 1·0 0·2 56·9 24·8
Sugars (g) 3·5 0·0 1·0 0·2 4·7 2·1
Protein (g) 13·9 0·0 26·0 6·8 46·7 20·4
Fat (g) 1·7 20·0 27·0 5·7 54·4 53·4
SFA (g) 0·6 10·0 11·6 1·7 23·9 23·5
MUFA (g) 0·3 8·0 12·3 2·2 22·8 22·4
PUFA (g) 0·8 2·0 3·1 1·0 6·9 6·7
* Adapted from Schwander et al.(19).
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arrived in a fasted state and a standard clinical assessment that
included body weight and composition was carried out
(bioimpedance analysis with ImpDF50). A Venﬂon catheter was
placed laterally in the arm of the participant, and after a resting
period of 20min, the ﬁrst fasting blood sample was taken.
The volunteer was then given the test meal, and 6-h post-
prandial sampling was initiated. A visual analogue scale ques-
tionnaire (based on the work of Flint et al.(21)) was used to
assess satiation in the fasted state and postprandially until test
completion.
Sampling
Blood samples were taken at selected time points during the
test days (Fig. 1(b)). No blood sampling was done after the
completion of wash-out 2. Serum, plasma and whole-blood
samples (PAXgene® collection tubes; Qiagen) were prepared
according to standard protocols for the selected biomarker.
Samples for LPS endotoxin analysis were prepared in sterile
tubes (0·2% heparin). All blood samples were stored at –80°C.
A total of eight faecal samples were collected from the
participants during the study (Fig. 1(a)). These samples were
processed under sterile conditions within 4 h of sample
collection. Aliquots (200mg) were added to 2ml of glycerol–
brain heart infusion solution (100ml glycerol, 37 g Brain Heart
Solution, 1 litre distilled water). Following homogenisation by
agitation (13 g, 10min), samples were stored at –80°C. Samples
were washed three times with PBS (centrifugation 16 000 g,
2min) and suspended at 95°C before DNA extraction, which
was performed using the QIAamp Fast DNA Stool Mini Kit
(Qiagen). Urine samples were collected as a fasted ‘spot test’
and as a single pooled sample for the 6 h of each test day using
a tube with no additives.
Metabolic and inﬂammatory marker analyses
Classical parameters of metabolic health and selected circulating
inﬂammatory markers were analysed at selected time points
on the test days (Fig. 1(b)). The COBAS® 8000 platform
(Roche Diagnostics International AG) was used to assess
routine biomarkers (insulin was assessed by the electro-
chemiluminescence immunoassay assay, all other biomarkers
were measured as previously described by van Leckwyck
et al.(22)). NEFA were assessed using Wako reagents for NEFA
analysis (Wako Diagnostics) on the Pentra 400
platform (ABX; Horiba). Endotoxin levels were assayed using
QCL-1000 LAL endpoint assay (Lonza). IL6 and TNFα con-
centrations were measured by the Bio-Plex ProTM Human
Cytokine Standard 27-plex, Group 1 assay (BioRad)(23) (intra-
assay CV 0·52% for TNFα, 0·48% for IL6; inter-assay CV 17% for
IL6, 8% for TNFα). Chemokine ligand 2 (CCL2) and chemokine
ligand 5 (CCL5) concentrations were measured with the
Bio-Plex ProTM Human Cancer Biomarker Panel 2, 2-plex assay
(BioRad) (intra-assay CV 1·5% for CCL2, 1·1% for CCL5; inter-
assay CV 23% for CCL2, 24% for CCL5). Both assays were
completed using the Luminex® MAGPIX® system (Luminex®
Cooperation) that applies magnetic bead methodology. All kits
for cytokine and chemokine assessments were from the same
kit production batch and all samples from the same volunteer
were analysed on the same plate to limit the effect of inter-assay
variability. These analyses were performed according to the
manufacturer’s instructions.
Analysis of faecal microbiota
DNA libraries were prepared with the extracted faecal DNA using
the 16S Metagenomic Sequencing Library protocol, as deﬁned by
the Illumina MiSeq System. Primers S-D-Bact-0341-b-S-17 and
S-D-Bact-0785-a-A-21 were chosen to target the V3–V4 regions of
the bacterial genome(24). Veriﬁcation of the library quality was
completed using the Fragment Analyzer (Advanced Analytical).
Sequencing was completed on the Illumina MiSeq and read-
quality analysis assessed on the Illumina BaseSpace platform.
Nutritional and physical activity analyses
Accelerometry data were analysed with ActiLife 6 (version 6.10.0).
Wear-time validation was completed using the Choi
algorithm(25). Data were included in the analysis if the total
wear-time for the day assessed exceeded 8 h(26,27). Outcome
parameters were total vector magnitude counts, average
vector magnitude counts, counts in light, moderate, vigorous,
very vigorous and combined moderate-vigorous activities
(Freedson Adult VM3 reference cut-off points(28)), total number
of bouts, total counts during bouts, sedentary bouts, activity
energy expenditure, metabolic equivalent of task(29), and wear-
time.
Food-intake records were analysed by a registered dietitian
using the Nutrilog software, version 2.70 with the databases
OSAV 5.1(30), Ciqual(31), Aliments de Marques(32) and manual
entry of nutritional data, if available. Total energy intake and
macronutrient intake were assessed for all test periods.
Bioinformatic data processing
The raw paired-reads were assembled into contigs using Panda-
seq software(33). Only contigs without any ambigous nucleotides
and with a length between 390 and 450 nucleotides were retained
in the subsequent analysis. Reference operational taxonomic unit
(OTU) sequences were selected using the USEARCH pipeline(34)
using the full data set after discarding sequences that were not
repeated at least ten times across all samples. Three sequences
related to yogurt strains were manually added to the set of OTU
reference sequences: Streptococcus salivarius spp. thermophilus,
L. delbrueckii spp. lactis and Lactobacillus casei/paracasei. The
ﬁnal abundance of OTU in each sample was counted using the
USEARCH package(34).
The 16S rRNA sequences together with taxonomic annota-
tions were downloaded from SILVA database (version 123)(35).
All sequences with a pintail quality score(36) < 0·9 were
removed from the database. The reference sequences for OTU
were mapped against the database and taxonomy was assigned
to the OTU on the basis of best hits, ensuring that the obtained
nucleotide similarity exceeded 97%. The species level assign-
ment was kept only in cases of sequences that displayed
similarity exceeding 99%. Any sequence that was unassigned
using this method was further subjected to classiﬁcation using
online SINA alignment service with default parameters(37).
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Statistical analyses
The study was designed with two objectives: (1) to explore
the changes of metabolomic parameters during postprandial
dairy product tests and (2) to study the impact of short-term
dairy intake on inﬂammation. The sample number was chosen
to reﬂect the exploratory nature of the ﬁrst objective of the
study within a highly controlled study design. We report here
the results of our second objective. The desired sample number
could not be determined because of the absence of previous
clinical studies with a similar intervention.
All statistical analyses were performed using R (version 3.2.4)(38)
with applied packages MESS (version 0.3–2)(39), DESeq2
(version 1.10.1)(40), phyloseq (version 1.14.0)(41) and dendex-
tend (version 1.1.8)(42). The Wilcoxon signed-rank test was
used to compare the effect of the two dairy product interven-
tions on fasting biomarkers and on the postprandial response
to the HFM. Differences were considered signiﬁcant at
P≤ 0·05. Fasting assessments were evaluated by calculating the
respective change after each intervention compared with the
baseline levels at the beginning of each test phase. Linear
evaluation of the incremental AUC was completed to assess the
postprandial response to the HFM (MESS package(39)). Missing
data points for the postprandial response were treated by
extrapolation of the postprandial curve where possible, or data
were removed if the missing data concerned fasting time points.
A pre-test was completed to conﬁrm the assumption of negli-
gible carryover effects, as described by Wellek & Blettner(43).
The treatment effect was then assessed by calculating within-
subject differences for the two sequence groups. The response
to the HFM after the dairy product administration was also
compared with the baseline response to this test. For this eva-
luation, the response to each dairy product was compared
separately with the baseline test using pairwise comparisons for
all subjects pooled, given that all baseline tests preceded the
dairy product interventions and no carryover effects were
observed. Dietary intake and physical activity changes were
assessed using the Kruskal–Wallis rank-sum test using P≤ 0·05
to deﬁne signiﬁcant differences.
Microbiota analysis was completed on taxa present at a mini-
mum mean abundance of 0·01%/volunteer, in at least three
volunteers. Cluster analysis was completed at the species level
using Spearman’s correlation (amap, version 0.8–1.4(44)). DESeq2
was used to complete differential analyses on the microbiota
using the Wald test and with signiﬁcance assessed with
Padj≤ 0·05(40) (Benjamini–Hochberg correction(45)). The micro-
biota composition after each test phase was compared directly
and analysis was also completed separately for each intervention
phase with comparison with pooled samples from all normal-milk
phases (run-in, wash-out 1 and wash-out 2). Carryover effects of
the intervention were assessed by comparison of samples from
wash-out phases after the respective interventions. Time-course
changes were assessed by pairwise comparison of each normal-
milk phase. In view of the signiﬁcant inter-individual variation,
analysis was completed using samples from volunteers who
provided at least one viable faecal sample for each condition
being compared in the differential analysis. Diversity indices were
assessed by Phyloseq(41), using the Shanon and Simpson indices.
Results
Participant characteristics
A total of fourteen healthy young men were enrolled in the
study and randomly allocated to one of the two test sequences
(group 1: acidiﬁed milk–probiotic yogurt; group 2: probiotic
yogurt–acidiﬁed milk) (online Supplementary Fig. S2). One
subject from group 1 was excluded from all analysis because of
suspected non-compliance with dietary restrictions that was
detected during the microbiota analysis. High levels of the OTU
for L. casei and L. paracasei were detected for this volunteer
during the second wash-out phase (faecal sample 7) (online
Supplementary Fig. S3(J)). These two bacterial strains are
widely used in cheese fermentation and added to dairy
products for their probiotic qualities(46,47). The distinct spike in
the number of reads apparent for faecal sample 7, together with
the absence of the bacteria in all other conditions, is consistent
with a discrete intake of a prohibited fermented or probiotic
food. Furthermore, negligible counts for the three probiotic
yogurt strains were detected for this volunteer after the con-
sumption of the probiotic yogurt (online Supplementary Fig. S3
(B, G)). The absence of bacterial strains for all other volunteers
during run-in, wash-out and acidiﬁed milk phases (online
Supplementary Fig. S3 (A, C–F, H, I)) indicate compliance
with the dairy product dietary restrictions. A second subject
(group 2) did not complete the ﬁnal visit (post-acidiﬁed milk)
because of acute illness. All the analysis concerning probiotic
yogurt was thus completed with twelve participants, whereas
the analysis of acidiﬁed milk was completed with thirteen
participants. Baseline clinical parameters were all within the
respective reference ranges (Table 2) and showed no difference
between the two groups, except for BMI, which was sig-
niﬁcantly higher for sequence group 1.
Table 2. Participant characteristics
(Medians and interquartile ranges (IQR))
n Median IQR
Age (years) 13 24·0 22·0–27·0
Weight (kg) 13 71·2 67·2–75·7
BMI (kg/m2) 13 22·09 20·0–22·69
Fat-free mass (%) 13 82·9 79·2–85·4
Fat mass (%) 13 17·1 14·6–20·8
Estimated energy requirements (MJ/d) 13 11·5 10·9–11·9
Estimated protein requirements (g/d) 13 71·2 67·2–75·7
DBP (mmHg) 13 69 67–77
SBP (mmHg) 13 128 120–133
Heart rate (beats per min) 13 58 52–62
Glycaemia (mmol/l) 13 4·7 4·6–4·9
Insulin (mU/l) 13 3·7 3·0–4·6
HOMA score 13 0·8 0·6–1·02
HbA1c (%) 13 5·0 4·8–5·3
TAG (mmol/l) 13 0·7 0·7–09
Total cholesterol (mmol/l) 13 3·9 3·6–4·3
HDL-cholesterol (mmol/l) 13 1·3 1·2–1·5
LDL-cholesterol (mmol/l) 13 2·0 1·8–2·3
Microbiota biodiversity
Shannon Index 13 2·9 2·79–3·22
Inverse Simpson Index 13 6·89 5·32–12·37
DBP, diastolic blood pressure; SBP, systolic blood pressure; HOMA, homoeostatic
model assessment; HbA1c, glycosylated Hb, type A1c.
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Dietary and physical activity analyses
Dietary intake during the different phases of the study was not
signiﬁcantly different for macronutrients (P> 0·05) (online
Supplementary Table S3). In addition, energy expenditure
assessed by Actigraph accelerometers showed no signiﬁcant
changes between test phases for sedentary, low, moderate-
vigorous activity, or for total accelerometer counts by test phase
(P> 0·05); however, a trend of higher levels of moderate-
vigorous as well as total counts was observed during the run-in
phase (online Supplementary Table S4).
Fasting analyses
No changes in fasting metabolic and inﬂammatory markers
were observed after 2 weeks’ probiotic yogurt intake compared
with acidiﬁed milk intake, except for CCL2, which showed a
greater increase after acidiﬁed milk intake (P= 0·01) (online
Supplementary Table S5). The cross-over analysis of the change
in fasting markers suggested a difference between the volun-
teers in sequence groups 1 and 2 for insulin; however, no
intervention effect was observed for this marker. In addition,
no signiﬁcant changes were observed for anthropometric
measurements or body composition (data not shown).
High-fat meal test response
No signiﬁcant differences were observed after probiotic yogurt
intake compared with after acidiﬁed milk intake for any of the
inﬂammatory and metabolic biomarkers used to assess the
postprandial response to the HFM. However, the responses for
IL6, CCL5 and TNFα to the HFM were signiﬁcantly reduced after
both interventions in comparison with the baseline evaluations
that were completed during the run-in phase (P< 0·001)
(Fig. 2). A negative outlier was observed for all three bio-
markers due to a raised fasting level of inﬂammation for one
volunteer; however, given the use of non-parametric statistical
tests, these data did not signiﬁcantly alter the results. The
maximum response for these biomarkers during the baseline
(HFM1) test was observed between 90 and 120min (online
Supplementary Fig. S4). The postprandial response for inﬂam-
matory markers high-sensitivity C-reactive protein (hsCRP) and
LPS, and metabolic biomarkers were not signiﬁcantly different
after probiotic yogurt or acidiﬁed milk intakes, compared with
baseline assessments (data not shown).
Microbiota
Cluster analysis of the microbiota data revealed a strong inter-
individual variability at the OTU level, with all samples from the
same volunteer being clustered together without exception
(online Supplementary Fig. S5). Similar grouping was observed
at the species and genus levels (data not shown).
The abundance of several bacteria was signiﬁcantly different
after the probiotic yogurt intervention compared with after the
acidiﬁed milk intervention (online Supplementary Table S6).
Notably, the two strains used in the fermentation process,
S. salivarius spp. thermophilus and L. delbrueckii spp.
bulgaricus, were both signiﬁcantly more abundant after probiotic
yogurt intake (log 2-fold-change (FC)= 7·6 and 3·6, respectively,
Padj< 0·01). The strain Intestinibacter bartlettii was also more
abundant after probiotic yogurt intake than after acidiﬁed milk
intake (FC= 2·1, Padj< 0·01). Conversely, the Biﬁdobacterium
kashiwanohense or Biﬁdobacterium pseudocatenulatum strains
and the Megasphaera genus were less abundant after probiotic
yogurt intake than after acidiﬁed milk intake (FC= –1·7,
Padj< 0·01 and FC= –1·7, respectively, Padj= 0·03). These differ-
ences were consistently observed at the different taxonomic
levels analysed.
Analysis of each intervention phase separately with respect to
the baseline (normal milk) phases conﬁrmed the speciﬁcity of
the differences observed between the interventions (online
Supplementary Tables S7 and S8). Transient increases in the
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Fig. 2. Postprandial response for inflammatory markers, (a) TNFα, (b) IL6 and
(c) chemokine ligand 5 (CCL5), to the high-fat meal test at baseline and after
the 2-week intake of acidified milk or probiotic yogurt. iAUC, incremental AUC.
* P< 0·001.
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relative abundance of S. salivarius spp. thermophilus and
L. delbrueckii spp. bulgaricus were observed speciﬁcally after
probiotic yogurt compared with baseline assessments (FC= 6·0
and 7·0, respectively, Padj.< 0·001) with no changes in the
abundance of these strains after acidiﬁed milk intake compared
with baseline (Fig. 3(a) and (b)). A non-signiﬁcant increase in
abundance was observed for the probiotic strain LGG after
probiotic yogurt intake but not after acidiﬁed milk intake
(Fig. 3(c)). The difference in abundance of B. kashiwanohense
or B. pseudocatenulatum between the two interventions was
shown to represent, speciﬁcally, a relative increase in the strains
after acidiﬁed milk intake compared with baseline phases
(Fig. 3(e)) (FC= 1·4, Padj= 0·04), with signiﬁcant effects visible
at all taxonomic levels evaluated. These species were not
modulated by probiotic yogurt intake compared with baseline
phases. The change in abundance of I. bartlettii was also
associated with the acidiﬁed milk intake rather than the pro-
biotic intervention, with signiﬁcant differences in the abun-
dance of the OTU for the strain after acidiﬁed milk intake,
compared with baseline assessments (FC= –1·7, P= 0·04).
In addition, this analysis revealed further modulation
of bacteria by the acidiﬁed dairy product interventions.
Notably, signiﬁcant reductions in abundance for the species
Bilophila wadsworthia were observed after both acidiﬁed
milk and probiotic yogurt intakes, with respect to baseline
assessments (FC= –1·5, Padj= 0·05 after acidiﬁed milk intake;
FC= –1·3, Padj= 0·03 after probiotic yogurt intake) (Fig. 3(d)).
These changes were observed at all levels of taxonomic
assessments up to and including class level. Speciﬁc changes in
the abundance of the species Haemophilus parainﬂuenzae
and six genera were observed after probiotic yogurt intake
compared with baseline phases. Acidiﬁed milk was associated
with relative reductions in the abundance of four OTU of
unknown species, and relative increases in abundance of two
OTU of unknown species (classiﬁed at the genus level as
Ruminococcaceae UCG-014 and Lachnospiraceae UCG-004)
compared with baseline phases.
Carryover analysis showed no signiﬁcant changes of any taxa
when comparing the wash-out after acidiﬁed milk intake with
that completed after probiotic yogurt intake (data not
shown). However, comparisons of the wash-out phases in
study chronological order showed signiﬁcant changes for the
Clostridiaceae Family XIII AD3011 group that was also
observed at higher taxonomic classiﬁcations from family to class
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Fig. 3. Changes in selected bacterial species after intake of probiotic yogurt and acidified milk: (a) Lactobacillus delbrueckii spp. bulgaricus; (b) Streptococcus
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level (online Supplementary Table S9)). Differences in bacteria
were also observed in comparisons between the run-in phase
and the two wash-out phases. Two OTU were different
between the run-in and wash-out phase 1, and a further two
OTU were different between the run-in and wash-out phase 2
(online Supplementary Tables S10 and S11).
Discussion
In this cross-over study, probiotic yogurt, compared with acidi-
ﬁed milk, did not signiﬁcantly modulate the postprandial
inﬂammatory response associated with a HFM; however, both
products similarly and signiﬁcantly reduced this inﬂammatory
response, compared with baseline assessments, in our relatively
small cohort of healthy young men. These effects were observed
in parallel to distinct changes in taxa of the gut microbiota
including Lactobacillus, Streptococcus, Biﬁdobacterium, Bilophila
and Ruminococcaceae. The modulation of the microbiota during
the acidiﬁed milk intervention could be a mechanism for the
unexpected effects of this dairy product on the inﬂammatory
response.
We explored postprandial inﬂammation using a HFM model
and observed that daily intake of probiotic yogurt and acidiﬁed
milk similarly moderate this response. The use of ‘challenge’
tests such as our HFM can unveil metabolic adaptations that are
not detectable in the fasted state. The model simulates physio-
logical exposures to excessive energetic loads and con-
sequentially aims to approach the reality of how the response to
dietary excess can be modulated by other dietary components.
Although such tests have been used in acute dietary interven-
tions(48,49), few studies have applied the test after a longer
exposure to a dietary stimulus(50). Our ﬁndings conﬁrm the
usefulness of such an approach for evaluating inﬂammation
associated with diet in a healthy population. One of the chal-
lenges of evaluating the inﬂammatory response in clinical
studies is the absence of universally accepted biomarkers(51).
Using a selection of sensitive blood biomarkers, we detected
changes in inﬂammatory parameters. As in the case of all
biomarkers, the clinical signiﬁcance of these ﬁndings needs to
be further validated with clinical outcomes. Nevertheless, it was
remarkable that we observed a consistent modulation of the
IL6, TNFα and CCL5 responses to the HFM by the probiotic
yogurt and acidiﬁed milk, with respect to baseline tests. Little
response to the HFM was observed for hsCRP or LPS both for
the baseline tests and tests after the intervention. This may
relate to the sensitivity of the markers or could reﬂect the
‘metabolic ﬂexibility’ of the healthy volunteers, which seeks to
maintain homoeostatic control(19).
The role of dairy products in inﬂammation is controversial,
with evidence for both positive and negative effects described
in a recent review of ﬁfty-two clinical trials(17). Overall, a
protective role of dairy products on inﬂammation was sug-
gested in this review, although it was noted that dairy product
characteristics and the health status of the population studied
inﬂuenced this relationship. Given that our baseline challenge
test was completed after a run-in period during which normal
milk was consumed, it cannot be excluded that the apparent
beneﬁts we observe rather represent a relative reduction in
inﬂammation, compared with stimulation of inﬂammatory
parameters by normal milk. Unfortunately, the absence of
blood sampling before all milk interventions or following the
reintroduction of the participants’ normal diets prevented us
from testing this hypothesis. Nevertheless, in view of the
nutritional qualities of bovine milk, the distinct effects of both
probiotic yogurt and acidiﬁed milk on inﬂammation remain an
interesting ﬁnding.
The concept of modulating the intestinal microbiota in a
targeted manner is important in view of the wide number of
diseases that are associated with dysbiosis of the intestinal
microbiota(52). In the current study, we concur with existing
research that demonstrates the highly individual nature of the
microbiota composition(53) and the relative stability of this
identity over time(54). Indeed, in previous work with salivary
microbiota samples, we have already evoked the notion of
the microbiota composition as a novel ﬁngerprint which can
differentiate individuals(55). The stability of this identity is
supported by a recent study that examined the microbiota
changes following an antibiotic intervention(56). Despite a rapid
perturbation of the microbiota following antibiotic treatment,
the inter-individual variability was still largely present following
the intervention. Similarly, we observe a signiﬁcant but distinct
modulation of different taxa during the dairy product inter-
ventions, whereas the individual identity of the microbiota is
maintained. Notably, the acidiﬁed milk intervention is asso-
ciated with a signiﬁcant increase in Biﬁdobacterium sp. OTU,
which attests to the previously described function of gluconic
acid as a prebiotic ingredient(57,58). Whereas gluconic acid has
already been used in isolation to induce an increase in this
species(57), this is the ﬁrst study to demonstrate this quality in a
dairy product formulation. Biﬁdobacteria have been associated
with multiple health beneﬁts, including beneﬁts on metabolic
and inﬂammatory parameters(15,59). The use of gluconic acid,
transformed from glucono-δ-lactone, in combination with a
probiotic dairy product, could be an interesting symbiotic
approach to maximise the action of the probiotic.
The impact of our probiotic yogurt on the gut microbiota was
highly speciﬁc to the strains that were present in the product,
with limited effect on the commensal microbiota. These
ﬁndings are in agreement with previous studies that investigated
probiotics and in which the gut microbiota was studied(60). The
relatively low abundance of LGG in the probiotic yogurt culture
explains the absence of signiﬁcant increases of this strain after
the probiotic yogurt test phase, despite the inoculation count
exceeding that which has been previously established in
dairy products as adequate to ensure faecal recovery of the
probiotic(61). One reason for this lower dosage was that at
higher inoculation, LGG showed a strong inhibitory effect on
the fermenting yogurt strain, L. delbrueckii spp. bulgaricus.
Given the beneﬁcial qualities of the yogurt fermenting strains,
we opted for a compromise that would favour the growth of the
fermenting strains while also meeting minimum levels of LGG
to ensure faecal recovery. It should thus be noted that the
effects that we observe on inﬂammation are the combination of
a mixed culture including fermenting bacterial strains and LGG.
The role of probiotic interventions in metabolic dysfunction is
not clear, with an absence of effects reported in some
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studies(11,62,63), although there is some evidence for a role
of LGG in reducing inﬂammation(9,64) and even a report for
the role of conventional yogurt in modulating inﬂammatory
markers(10). In our study, we used a relatively low inoculation
of LGG, compared with the work of Kekkonen et al.(9) in which
beneﬁts on fasting inﬂammatory biomarkers were observed;
however, effects on inﬂammation in healthy populations have
been observed at this dosage(64). Further research on the
different bacteria used and their relative dosage could provide
insight into the positive effects observed on inﬂammation in
our work and may even reveal beneﬁts on fasting markers of
inﬂammation.
A common reduction after acidiﬁed milk and probiotic yogurt
intakes was observed for the strain B. wadsworthia. The pre-
sence of this strain has been associated with acute infections(65),
and is modulated by probiotic dairy product interventions(66).
Veiga et al.(67) recently demonstrated that consumption of a
fermented milk product decreased the abundance of this
opportunistic pathogen in subjects with irritable bowel syn-
drome. The pro-inﬂammatory activity of B. wadsworthia in the
presence of saturated fat appears to be mediated by its impact
on bile salt metabolism and, consequently, lipid uptake(68).
Interestingly, B. wadsworthia is increased in mice fed a
fat-enriched Western diet(69). Our results using full-fat dairy
products are in line with evidence in the scientiﬁc community to
reappraise the impact of dairy foods and milk fat on CVD
risk(70).
In our study, metagenomic analysis proved to be a sensitive
method that not only showed changes during the interventions
but also supported the veriﬁcation of the compliance of the
volunteers with the dairy dietary restrictions. In view of this, we
suggest that 16S rRNA PCR-based microbiota analysis could be a
useful, accessible tool for the evaluation of compliance in
probiotic interventions.
One explanation for the association between a high-fat diet,
inﬂammation and the gut microbiota is the transfer of
microbiota-derived LPS during lipid uptake(13,14). Whereas we
observe a change in bacteria present in the microbiota as well
as modulation of inﬂammatory parameters during our HFM, we
were unable to distinguish a signiﬁcant change in LPS response
as persistently low levels of the biomarker were observed on all
test days. Given the healthy population studied, it is con-
ceivable that a small change in circulating LPS could lead to
larger, measurable changes in circulating interleukins and
chemokines. However, these associations may be better eluci-
dated in a population with existing sub-clinical inﬂammation.
The major strengths of our study are the highly controlled
nature of the dietary intervention that included an identical, 3-d
controlled diet before each test day. The use of a cross-over
design was also an important aspect of the study that facilitated
the identiﬁcation of microbiota changes during the intervention.
Given the inter-individual variability in both the baseline
microbiota and in the relative changes of the microbiota, use of
a parallel study design may not have been adequately sensitive
to detect these effects. One unexpected ﬁnding in our study
was the role of the acidiﬁed milk on both the microbiota and the
biomarkers of inﬂammation. This latter effect has not previously
been described although there is evidence for the role of other
prebiotic foods in modulating inﬂammation(71). Whereas the
study design was not speciﬁcally adapted to observe an effect
of acidiﬁed milk, the baseline tests completed during the run-in
phase allowed the effects of the acidiﬁed milk to be assessed
compared with normal milk. In consideration of the anti-
inﬂammatory effects associated with acidiﬁed milk, it would be
interesting to explore whether the combined use of acidiﬁed
milk supplemented with probiotic strains could have greater
effects of inﬂammation.
The current study supports a beneﬁcial role of milk supple-
mented with probiotics and prebiotic ingredients on inﬂam-
mation associated with a high-fat diet. These beneﬁts may be
modulated by modiﬁcation of the gut microbiota mediated by
the probiotic and prebiotic qualities of the tested products.
These foods could form a useful part of interventions for
populations at risk for inﬂammation.
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